JCB logo
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 15 November 2004. doi:10.1083/jcb1674iti2
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 167, Number 4, 578-578
This Article
Right arrow Full Text (PDF, 542K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tuma, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tuma, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In This Issue

ES cells without teratomas



Ceramide leaves stem cells free to form neurons.

Therapeutic use of embryonic stem cells may be hampered by their proclivity to form pluripotent tumors called teratomas. On page 723, Bieberich et al. describe the use of a ceramide analogue, S18, to induce apoptosis in a subpopulation of embryoid body–derived stem cells (EBCs). Cells that survive the treatment express the neural marker nestin and differentiate into neural progenitors when injected into the brains of young mice. They do not form teratomas.

The S18 selectively affects those EBCs that express prostate apoptosis response-4 (PAR-4) protein, an endogenous inhibitor of atypical PKC{zeta}. Significantly, the majority of the PAR-4–expressing cells also express Oct-4, a marker for pluripotency. Almost all Oct-4+ cells were positive for PAR-4, suggesting that teratoma formation might be prevented via elimination of PAR-4-expressing cells with ceramide-induced apoptosis before injection into animals. Sure enough, after injection into the brains of mice, treated cells differentiated into neural cells and some benign tumors, but no invasive tumors. Untreated cells gave rise to a significant number of teratomas in the same animals.

Bieberich et al. hypothesize that coexpression of Oct-4 and PAR-4 may indicate that the expression of PAR-4 is specifically up-regulated at particular stages during ES cell differentiation. Discovering the function and mechanism behind this up-regulation is the next task the team plans to tackle. {iti_end}



Rabiya Tuma

rabiya{at}nasw.org


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 542K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tuma, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tuma, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents